A Phase 2, Open-Label, Sequential Dose Escalation Study in Adult Hypogonadal Males to Evaluate the Pharmacokinetics of Three Volumes of FE 999303 (Testosterone Gel), Applied to the Shoulder/Upper Arm, Using an Applicator Compared With Hand Application
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 30 Jul 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2011 Planned End Date changed from 1 Feb 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.